495 related articles for article (PubMed ID: 29035367)
21. Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
Schmid RS; Simon JM; Vitucci M; McNeill RS; Bash RE; Werneke AM; Huey L; White KK; Ewend MG; Wu J; Miller CR
Neuro Oncol; 2016 Jul; 18(7):962-73. PubMed ID: 26826202
[TBL] [Abstract][Full Text] [Related]
22. Effects of Enhancer of Zeste Homolog 2 (EZH2) Expression on Brain Glioma Cell Proliferation and Tumorigenesis.
Cheng T; Xu Y
Med Sci Monit; 2018 Oct; 24():7249-7255. PubMed ID: 30305602
[TBL] [Abstract][Full Text] [Related]
23. Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer.
Gimple RC; Bhargava S; Dixit D; Rich JN
Genes Dev; 2019 Jun; 33(11-12):591-609. PubMed ID: 31160393
[TBL] [Abstract][Full Text] [Related]
24. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma.
Natsume A; Ito M; Katsushima K; Ohka F; Hatanaka A; Shinjo K; Sato S; Takahashi S; Ishikawa Y; Takeuchi I; Shimogawa H; Uesugi M; Okano H; Kim SU; Wakabayashi T; Issa JP; Sekido Y; Kondo Y
Cancer Res; 2013 Jul; 73(14):4559-70. PubMed ID: 23720055
[TBL] [Abstract][Full Text] [Related]
25. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
26. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
27. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2.
Wang J; Cheng P; Pavlyukov MS; Yu H; Zhang Z; Kim SH; Minata M; Mohyeldin A; Xie W; Chen D; Goidts V; Frett B; Hu W; Li H; Shin YJ; Lee Y; Nam DH; Kornblum HI; Wang M; Nakano I
J Clin Invest; 2017 Aug; 127(8):3075-3089. PubMed ID: 28737508
[TBL] [Abstract][Full Text] [Related]
28. Targeting role of glioma stem cells for glioblastoma multiforme.
Zhang X; Zhang W; Mao XG; Zhen HN; Cao WD; Hu SJ
Curr Med Chem; 2013; 20(15):1974-84. PubMed ID: 23317162
[TBL] [Abstract][Full Text] [Related]
29. CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia.
Mao XG; Xue XY; Wang L; Zhang X; Yan M; Tu YY; Lin W; Jiang XF; Ren HG; Zhang W; Song SJ
Neuro Oncol; 2013 Jul; 15(7):865-79. PubMed ID: 23645533
[TBL] [Abstract][Full Text] [Related]
30. The hypoxic peri-arteriolar glioma stem cell niche, an integrated concept of five types of niches in human glioblastoma.
Aderetti DA; Hira VVV; Molenaar RJ; van Noorden CJF
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):346-354. PubMed ID: 29684521
[TBL] [Abstract][Full Text] [Related]
31. Chromatin remodeler HELLS maintains glioma stem cells through E2F3 and MYC.
Zhang G; Dong Z; Prager BC; Kim LJ; Wu Q; Gimple RC; Wang X; Bao S; Hamerlik P; Rich JN
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30779712
[TBL] [Abstract][Full Text] [Related]
32. Knockdown of miR-210 decreases hypoxic glioma stem cells stemness and radioresistance.
Yang W; Wei J; Guo T; Shen Y; Liu F
Exp Cell Res; 2014 Aug; 326(1):22-35. PubMed ID: 24930954
[TBL] [Abstract][Full Text] [Related]
33. The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma.
Bhaskaran V; Nowicki MO; Idriss M; Jimenez MA; Lugli G; Hayes JL; Mahmoud AB; Zane RE; Passaro C; Ligon KL; Haas-Kogan D; Bronisz A; Godlewski J; Lawler SE; Chiocca EA; Peruzzi P
Nat Commun; 2019 Jan; 10(1):442. PubMed ID: 30683859
[TBL] [Abstract][Full Text] [Related]
34. Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma.
Jiang W; Finniss S; Cazacu S; Xiang C; Brodie Z; Mikkelsen T; Poisson L; Shackelford DB; Brodie C
Oncotarget; 2016 Aug; 7(35):56456-56470. PubMed ID: 27486821
[TBL] [Abstract][Full Text] [Related]
35. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.
Li Z; Bao S; Wu Q; Wang H; Eyler C; Sathornsumetee S; Shi Q; Cao Y; Lathia J; McLendon RE; Hjelmeland AB; Rich JN
Cancer Cell; 2009 Jun; 15(6):501-13. PubMed ID: 19477429
[TBL] [Abstract][Full Text] [Related]
37. Targeting A20 decreases glioma stem cell survival and tumor growth.
Hjelmeland AB; Wu Q; Wickman S; Eyler C; Heddleston J; Shi Q; Lathia JD; Macswords J; Lee J; McLendon RE; Rich JN
PLoS Biol; 2010 Feb; 8(2):e1000319. PubMed ID: 20186265
[TBL] [Abstract][Full Text] [Related]
38. Targeting of BMI-1 with PTC-209 inhibits glioblastoma development.
Kong Y; Ai C; Dong F; Xia X; Zhao X; Yang C; Kang C; Zhou Y; Zhao Q; Sun X; Wu X
Cell Cycle; 2018; 17(10):1199-1211. PubMed ID: 29886801
[TBL] [Abstract][Full Text] [Related]
39. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth.
Cheng L; Huang Z; Zhou W; Wu Q; Donnola S; Liu JK; Fang X; Sloan AE; Mao Y; Lathia JD; Min W; McLendon RE; Rich JN; Bao S
Cell; 2013 Mar; 153(1):139-52. PubMed ID: 23540695
[TBL] [Abstract][Full Text] [Related]
40. EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner.
Kim SH; Joshi K; Ezhilarasan R; Myers TR; Siu J; Gu C; Nakano-Okuno M; Taylor D; Minata M; Sulman EP; Lee J; Bhat KP; Salcini AE; Nakano I
Stem Cell Reports; 2015 Feb; 4(2):226-38. PubMed ID: 25601206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
